Brainomix has built its commercial position on a body of clinical evidence that is unusual for an AI imaging company at this stage. New guidance from NICE, the globally respected health assessor, endorses the use of Brainomix 360 Stroke, with Brainomix being one of only two companies granted this highly coveted endorsement. The company is expanding beyond stroke into new therapeutic areas with similar unmet needs—harnessing AI to transform diagnosis and treatment where it matters most.
Cyborg Score Rationale
In February 2026, Brainomix completed a Series C funding round totaling £18.8 million to accelerate US rollout of its AI-powered imaging platforms for stroke and lung fibrosis. The company demonstrates strong clinical validation, regulatory approval, and global market traction with NICE endorsement and FDA clearances, though as a private company its scale remains smaller than public competitors.
Top Insights
Brainomix 360 Stroke has been deployed nationwide to all stroke centers across Wales, with thrombectomy rates increasing by more than 44% as of 2026-07-08.
Brainomix e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans enabling clinicians to identify changes including subtle deteriorations over multiple scan timepoints.
The company has strategic partnerships with major players such as Medtronic Neurovascular for stroke care across Western Europe, 3DR Labs in the US, and life science companies like Boehringer Ingelheim and AstraZeneca for clinical trial support.
The company holds eight FDA clearances for its stroke platform and two for its e-Lung, positioning it for strong US commercial expansion.
Named Competitors
Aidoc — AI radiology decision support and imaging platform
Zebra Medical Vision — AI-powered imaging analysis for radiology and imaging biomarkers
Viz.ai — AI platform for stroke and critical care imaging alerting
Recent Developments
(February 2026) Series C funding extension of £4.8 million ($6.5m) bringing total to £18.8 million, led by Parkwalk Advisors, Hostplus, and new US-based investor Modi Ventures
(March 2025) Initial Series C close of £14 million from existing investors Parkwalk Advisors and Hostplus
(April 2025) Clinical study published in British Journal of Radiology evaluating real-world clinical performance of e-CTA software for stroke detection
Open the full interactive Brainomix report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.